Darzalex continued to gain market share in Q3, while Arzerra was once again a disappointment. Given the favourable development in FX, the revenue guidance was upgraded by DKK300m and, as operating expenses remain stable, the operating profit target also gets an uplift of similar magnitude. Considering that Arzerra has reported positive results in the multiple sclerosis setting, a turnaround might be on the cards, but Roche’s Ocrevus would be a threat.
08 Nov 2019
Strong Q3; guidance upgrade driven by FX
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q3; guidance upgrade driven by FX
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
08 Nov 2019 -
Author:
Sumit Sayal -
Pages:
3
Darzalex continued to gain market share in Q3, while Arzerra was once again a disappointment. Given the favourable development in FX, the revenue guidance was upgraded by DKK300m and, as operating expenses remain stable, the operating profit target also gets an uplift of similar magnitude. Considering that Arzerra has reported positive results in the multiple sclerosis setting, a turnaround might be on the cards, but Roche’s Ocrevus would be a threat.